DB:I3F

Stock Analysis Report

Executive Summary

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Infinity Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: I3F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

18.6%

I3F

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

-49.7%

I3F

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: I3F underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: I3F underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

I3FIndustryMarket
7 Day18.6%11.3%7.1%
30 Day-17.0%-8.0%-20.0%
90 Day-7.3%-22.7%-26.1%
1 Year-49.7%-49.7%-4.9%-5.1%-15.0%-17.5%
3 Year-72.4%-72.4%17.7%16.4%-18.8%-25.8%
5 Year-93.4%-93.4%-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Infinity Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Infinity Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: I3F (€0.83) is trading below our estimate of fair value (€97.11)

Significantly Below Fair Value: I3F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: I3F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: I3F is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate I3F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: I3F is overvalued based on its PB Ratio (6.5x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Infinity Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

46.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: I3F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: I3F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: I3F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: I3F's revenue (55.6% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: I3F's revenue (55.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if I3F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Infinity Pharmaceuticals performed over the past 5 years?

21.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: I3F is currently unprofitable.

Growing Profit Margin: I3F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: I3F is unprofitable, but has reduced losses over the past 5 years at a rate of 21.5% per year.

Accelerating Growth: Unable to compare I3F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: I3F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: I3F has a negative Return on Equity (-609.07%), as it is currently unprofitable.


Next Steps

Financial Health

How is Infinity Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: I3F's short term assets ($44.6M) exceed its short term liabilities ($9.7M).

Long Term Liabilities: I3F's short term assets ($44.6M) exceed its long term liabilities ($31.6M).


Debt to Equity History and Analysis

Debt Level: I3F is debt free.

Reducing Debt: I3F has no debt compared to 5 years ago when its debt to equity ratio was 3.2%.


Balance Sheet

Inventory Level: I3F has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if I3F's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: I3F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: I3F has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.7% each year.


Next Steps

Dividend

What is Infinity Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate I3F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate I3F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if I3F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if I3F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of I3F's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Adelene Perkins (59yo)

10.17s

Tenure

US$2,432,111

Compensation

Ms. Adelene Q. Perkins has been the Chief Executive Officer of Infinity Pharmaceuticals, Inc. since January 2, 2010 and has been its Chairman since November 2012. Ms. Perkins served as the President of Inf ...


CEO Compensation Analysis

Compensation vs Market: Adelene's total compensation ($USD2.43M) is above average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Adelene's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Adelene Perkins
Chairman & CEO10.17yrsUS$2.43m1.41% $642.5k
Lawrence Bloch
President & Treasurer3.17yrsUS$974.94k1.32% $601.8k
Melissa Hackel
Vice President of Finance3.17yrsno datano data
Jeffery Kutok
Executive VP & Chief Scientific Officer3yrsUS$1.20m0.15% $69.9k
Rossitza Alargova
Head of Pharmaceutical Development0.17yrno datano data
Seth Tasker
Senior VP3.67yrsUS$1.13m0.20% $89.9k
Jayne Kauffman
Senior Executive Coordinatorno datano datano data

3.2yrs

Average Tenure

52.5yo

Average Age

Experienced Management: I3F's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adelene Perkins
Chairman & CEO10.17yrsUS$2.43m1.41% $642.5k
Anthony Evnin
Independent Director13.5yrsUS$89.43k0.25% $113.6k
Michael Venuti
Independent Director16.83yrsUS$89.60k0.087% $39.7k
Norman Selby
Lead Independent Directorno dataUS$132.80k0.017% $7.9k
David Beier
Independent Director1.92yrsUS$122.23k0.010% $4.5k
Michael Kauffman
Independent Director2.92yrsUS$81.75kno data
Roy Herbst
Member of Scientific Advisory Board2yrsno datano data
Jeffrey Berkowitz
Independent Director6yrsUS$74.25k0.15% $67.6k
David Munn
Member of Scientific Advisory Board2yrsno datano data
Dmitry Gabrilovich
Member of Scientific Advisory Board2yrsno datano data

2.9yrs

Average Tenure

65yo

Average Age

Experienced Board: I3F's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.


Top Shareholders

Company Information

Infinity Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Infinity Pharmaceuticals, Inc.
  • Ticker: I3F
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$50.536m
  • Listing Market Cap: US$45.578m
  • Shares outstanding: 57.43m
  • Website: https://www.infi.com

Number of Employees


Location

  • Infinity Pharmaceuticals, Inc.
  • 1100 Massachusetts Avenue
  • Cambridge
  • Massachusetts
  • 2138
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INFINasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDSep 2006
I3FDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2006

Biography

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 21:26
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.